PUR Stock Overview
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Pure Biologics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł8.10 |
| 52 Week High | zł21.90 |
| 52 Week Low | zł5.01 |
| Beta | 1.23 |
| 1 Month Change | -1.58% |
| 3 Month Change | -43.36% |
| 1 Year Change | -54.85% |
| 3 Year Change | -92.94% |
| 5 Year Change | -72.91% |
| Change since IPO | -64.63% |
Recent News & Updates
Recent updates
Here's Why We're Watching Pure Biologics Spólka Akcyjna's (WSE:PUR) Cash Burn Situation
Dec 06
We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Aug 14Will Pure Biologics Spólka Akcyjna (WSE:PUR) Spend Its Cash Wisely?
Apr 30We Think Pure Biologics Spólka Akcyjna (WSE:PUR) Can Afford To Drive Business Growth
Jan 03We're Interested To See How Pure Biologics Spólka Akcyjna (WSE:PUR) Uses Its Cash Hoard To Grow
Apr 21Shareholder Returns
| PUR | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 1.3% | 0.8% | -3.1% |
| 1Y | -54.8% | -17.2% | 24.0% |
Return vs Industry: PUR underperformed the Polish Biotechs industry which returned -18% over the past year.
Return vs Market: PUR underperformed the Polish Market which returned 25.9% over the past year.
Price Volatility
| PUR volatility | |
|---|---|
| PUR Average Weekly Movement | 13.0% |
| Biotechs Industry Average Movement | 4.8% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in PL Market | 9.6% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: PUR's share price has been volatile over the past 3 months.
Volatility Over Time: PUR's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 56 | n/a | purebiologics.com |
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified aptamers for therapeutic and diagnostic use.
Pure Biologics S.A. Fundamentals Summary
| PUR fundamental statistics | |
|---|---|
| Market cap | zł26.96m |
| Earnings (TTM) | -zł31.72m |
| Revenue (TTM) | zł109.00k |
247.3x
P/S Ratio-0.8x
P/E RatioIs PUR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PUR income statement (TTM) | |
|---|---|
| Revenue | zł109.00k |
| Cost of Revenue | zł4.43m |
| Gross Profit | -zł4.32m |
| Other Expenses | zł27.40m |
| Earnings | -zł31.72m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 30, 2024
| Earnings per share (EPS) | -9.53 |
| Gross Margin | -3,960.55% |
| Net Profit Margin | -29,097.25% |
| Debt/Equity Ratio | 94.7% |
How did PUR perform over the long term?
See historical performance and comparison